TECHWIRE 30
(CIX: WRAL30)  1,115.09  up arrow+0.63  (0.06 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: Apple)  101.00  up arrow+0.14  (0.14 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NY: QUINTILES)  56.38  down arrow-0.78  (-1.36 %)  Updated: 01:17 PM EDT, Sep 17 2014
(OP: BASF SE)  99.29  up arrow+0.22  (0.22 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: BioCryst)  11.22  down arrow-0.12  (-1.06 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: BioDelivery)  17.14  down arrow-0.09  (-0.52 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: CEMP)  10.02  up arrow+0.11  (1.11 %)  Updated: 01:16 PM EDT, Sep 17 2014
(NQ: Cisco Systems)  25.26  up arrow+0.04  (0.14 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: Cree)  42.37  up arrow+0.74  (1.77 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: DARA)  1.12  down arrow-0.02  (-1.75 %)  Updated: 01:03 PM EDT, Sep 17 2014
(NY: EMC CORPORATION)  29.29  down arrow-0.26  (-0.88 %)  Updated: 01:18 PM EDT, Sep 17 2014
(NQ: Extreme Networks)  4.86  down arrow-0.12  (-2.41 %)  Updated: 01:16 PM EDT, Sep 17 2014
(NQ: FB)  76.37  up arrow+0.29  (0.38 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NY: GLAXOSMITHKLINE)  47.11  down arrow-0.2  (-0.41 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: GOOG)  583.01  up arrow+3.06  (0.53 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NY: IBM)  192.81  down arrow-0.15  (-0.08 %)  Updated: 01:18 PM EDT, Sep 17 2014
(NY: LH)  106.38  down arrow-0.63  (-0.59 %)  Updated: 01:17 PM EDT, Sep 17 2014
(OP: Lenovo Group)  31.12  up arrow+0.74  (2.44 %)  Updated: 12:33 PM EDT, Sep 17 2014
(NY: MRK)  59.74  down arrow-0.25  (-0.42 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: Microsoft Corp)  46.46  down arrow-0.31  (-0.65 %)  Updated: 01:18 PM EDT, Sep 17 2014
(NQ: NTAP)  43.00  up arrow+0.03  (0.07 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NY: NOVARTIS AG)  95.04  up arrow+0.66  (0.7 %)  Updated: 01:17 PM EDT, Sep 17 2014
(OP: Novozymes A/S)  44.99  down arrow-0.08  (-0.18 %)  Updated: 01:12 PM EDT, Sep 17 2014
(NY: PFIZER)  30.26  up arrow+0.21  (0.68 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: Pozen)  8.17  up arrow+0.08  (0.93 %)  Updated: 01:16 PM EDT, Sep 17 2014
(NY: RED HAT)  61.18  up arrow+0.45  (0.74 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: BBRY)  11.05  down arrow-0.01  (-0.09 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: Salix)  159.97  up arrow+4.1  (2.63 %)  Updated: 01:17 PM EDT, Sep 17 2014
(NQ: SQI)  16.02  down arrow-0.26  (-1.6 %)  Updated: 01:16 PM EDT, Sep 17 2014

Posts tagged “GSK”

August 29

US to begin tests of GSK's Ebola vaccine next week

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline. Beginning Tuesday, it will test 20 healthy adult volunteers to see if the virus is safe and triggers an adequate response in their immune systems.

Ebola virus    Ebola virus

Updated August 28

US to test GSK's vaccine for Ebola; Greenville lab could produce a treatment

A possible vaccine to treat the spreading Ebola outbreak in Africa could be coming from GSK. Plus, a lab in Greenville could be a site where a treatment is produced.

Ebola virus    Ebola virus

Updated August 14

Premium Lock Duke doctor warns against use of untested Ebola drugs

As more companies step up efforts to develop vaccines targeting ebola and the disease outbreak spreads in Africa, a doctor at Duke University warns that using untested drugs "could prove disastrous."

Updated August 12

Premium Lock Wall Street Journal report questions investor confidence in GSK's CEO

Another day, another headache in the global press for GlaxoSmithKline and its CEO Andrew Witty. This time it's an in-depth report in The Wall Street Journal in which some investors question Witty's performance as the drug giant fights lagging sales and scandal.

Updated August 11

Premium Lock GSK could have first ebola vaccine in 2015, world health official says

A World Health Organization official says the first ebola vaccine could be available in 2015. It's being developed by GlaxoSmithKline. However, the drug giant says "it's too early" to speculate on timing.

Ebola fight   Ebola fight

August 11

Premium Lock GSK-hired investigators face jail time; son blames Glaxo

China business   "The root of the problem really from where I'm sitting is the way GSK behaved in this matter," the son of convicted investigator tells London-based broadcaster Sky News. GSK has said it hired the couple to investigate a security breach but not bribery allegations.

Tags: GSK
August 8

Premium Lock Trial of British-US couple with Glaxo ties continues in China

China business   Peter Humphrey and Yingzeng Yu worked under contract for British pharmaceutical giant GlaxoSmithKline, which is accused in a separate case of bribing Chinese doctors and hospitals to use its products. Authorities have not indicated whether these two cases are linked as the fraud trial continues in China.

August 6

Premium Lock Latest news on Glaxo, Comcast, FCC and Google

Bulldog In the latest Bulldog roundup of life science and technology news: GSK gets a lift as Express Scripts reinstates lung drug Advair; Comcast initiates amnesty, free service for the poor; FCC's Friends and Family Plan; and Wikipedia link to be hidden in Google under 'right to be forgotten' law.

Updated August 5

Premium Lock Latest news on Microsoft, Apple, GSK, municipal broadband, Google and MCS

Bulldog In the latest Bulldog roundup of life science and technology news: The real difference between Microsoft and Apple; Novo Nordisk leapfrogs Glaxo as U.K. drug giant declines; U.S. Map shows more community-owned broadband networks than expected; Google email scan leads to sex offender arrest; and Metrics Contract Services adopt new name and logo.

July 29

Premium Lock China to put GSK-hired investigators on trial Aug. 8

GSK China's web page  A Shanghai court says American and British investigators who worked for drug maker GlaxoSmithKline will stand trial Aug. 8 on charges of illegally obtaining information on Chinese citizens.

July 24

Premium Lock GSK seeks regulator approval for malaria vaccine

Fighting malaria The experimental shot is the most advanced candidate vaccine for malaria but results from previous trials have been disappointing. Research published in 2012 showed the shot only reduced malaria cases by about 30 percent in babies aged six to 12 weeks, the target age for immunization.

Updated July 23

Premium Lock GSK sales, earnings slump; shares drop 5%; growth forecast slashed

GSK's HQ in London       Drug giant GlaxoSmithKline, hurt in part by a 20 percent decline in sales in China where the company is under criminal investigation, reports revenues and earnings that missed analysts' expectations on Wednesday. GSK also reduced its growth forecast for 2014 from as much as 8 percent to "basically similar" to 2013 and says it can't estimate what the financial impact could be from the China case.

July 23

Premium Lock CEO on the state of GSK: 'We're making significant progress'

Even with sales and profits declining sharply from a year ago, a cut in a growth forecast for this year and continuing legal issues resulting from a criminal investigation in China, GSK's chief executive officer Andrew Witty puts a positive spin on the state of the company in a video interview.

Top execs discuss GSK earnings, strategy Top execs discuss GSK earnings, strategy

July 15

Premium Lock GSK invests up to $25M in new drug manufacturing technology - in Pa., not N.C.

GlaxoSmithKline, which operates a huge drug manufacturing facility in Zebulon, is investing as much as $25 million to license a technology platform from a California firm as part of efforts to develop new drugs. But GSK isn't bringing the platform to N.C., at least initially.

GSK's R&D facility in RTP GSK's R&D facility in RTP

Updated July 14

Premium Lock China indicts U.S., British corporate investigators hired by GSK

China business   Chinese authorities have indicted British and American investigators hired by GlaxoSmithKline on charges of illegally obtaining and selling private information, state media reported Monday, as the Briton blamed the pharmaceutical company for misleading and using him.

Tags: GSK
July 7

Premium Lock US officials barred from trial of American in China linked to GSK investigation

GSK in China  U.S. diplomats will be barred from the trial in China of an American investigator for GlaxoSmithKline and her British husband who are charged with improperly selling personal information, according to a spokesman for the U.S. Embassy in Beijing.

Updated June 30

Premium Lock Sunday Times: Sex tape ignited GSK's China scandal

"Revealed: Sex tape blew open Glaxo's China bribery scandal," reads the big headline in the prestigious The Sunday Times says. A "clandestinely" filmed video of GSK's top China executive that was sent to GSK's CEO set off a company investigation that in turn ignited China's bribery probe against the drug giant, the paper says. In a statement to Reuters, GSK confirms the tape's existence.

Sunday Times report on its website Sunday Times report on its website

Updated June 4

Premium Lock GSK to pay $105M, including $2.5M to NC, for 'improper drug marketing'

GSK Headquarters      Drug giant GlaxoSmithKline will pay 44 states, including North Carolina, some $105 million to settle a case over improper drug marketing. North Carolina will receive $2.5 million. It's the third time since 2011 that GSK is paying N.C. as part of settlements for investigations.

June 2

Premium Lock Reports: GSK in $350M deal to develop cancer drugs

 GlaxoSmithKline has agreed to a deal worth more than $350 million with UK biotech company Adaptimmune to develop cancer drugs, the Financial Times reported on Monday.

Updated May 29

Premium Lock Even without a script, Bob Ingram can spin a crowd

The former Midwestern pharmaceutical sales rep "carried the bag" all the way to the office of CEO and chairman of GlaxoWellcome, and co-led its integration into today's GSK tells entrepreneurs they are the future as he reflects on a remarkable career.

Bob Ingram Bob Ingram

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll